IMPEDIMED LIMITED — AGM Information 2022

Oct 25, 2022

==> picture [230 x 54] intentionally omitted <==

26 October 2022

ASX ANNOUNCEMENT

2022 Annual General Meeting – Chairman’s Address

ImpediMed Limited ( ImpediMed ) (ASX:IPD) provides the attached Chairman’s address to be delivered at today’s Annual General Meeting commencing at 9.00am AEDT.

Authorised for release by the Company Secretary of ImpediMed Limited.

Contact Details

Investor relations Contact:

Mike Bassett, ImpediMed T: +61 407 431 432 E: mbassett@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit www.impedimed.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the

date when made. ImpediMed does not assume any obligation to publicly update or revise any forwardlooking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

ImpediMed Limited 2022 Annual General Meeting Chairman’s Address

It is exciting that after two years of remote general meetings that we are once again meeting in person. Being able to join management and meet with many of you in person has been long overdue and we look forward to continuing the inperson meetings into the future.

My first year as Chairman of the Board has seen many evolutions in the company and the achievement of several inflection points. Having moved over recent years from a pure R&D company to commercialization of the SOZO Digital Health Platform will position the company for the potential of greater growth in the future.

Much of this coming on the heels of the largest ever clinical trial in the lymphedema space. We maintain a positive outlook for reimbursement of SOZO patient tests through both medical guidelines and favorable outcomes from discussions with private insurance companies.

We continue to focus on other medical indications which will allow the SOZO Digital Health Platform to have a broader reach. The future release of SOZO Pro will hopefully make the expansion easier.

As a Board we were excited to announce that Dave Anderson was stepping into the role of Interim CEO. The depth and breadth of his background has been instrumental in continuing to move ImpediMed closer to long-term success.

With that, I am happy to turn the meeting over to Dave for a deeper discussion of the company’s operations and future direction to deliver meaningful data to healthcare providers and patients.

Mr Don Williams